- Home
- CANF vs NML Comparison
CANF vs NML Comparison
Compare CANF & NML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- NML
- Stock Information
- Founded
- CANF 1994
- NML 2012
- Country
- CANF Israel
- NML United States
- Employees
- CANF N/A
- NML N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- NML Finance/Investors Services
- Sector
- CANF Health Care
- NML Finance
- Exchange
- CANF Nasdaq
- NML Nasdaq
- Market Cap
- CANF 7.9M
- NML 454.4M
- IPO Year
- CANF N/A
- NML N/A
- Fundamental
- Price
- CANF $1.20
- NML $8.36
- Analyst Decision
- CANF Strong Buy
- NML
- Analyst Count
- CANF 2
- NML 0
- Target Price
- CANF $14.00
- NML N/A
- AVG Volume (30 Days)
- CANF 413.8K
- NML 219.3K
- Earning Date
- CANF 04-29-2025
- NML 01-01-0001
- Dividend Yield
- CANF N/A
- NML 9.75%
- EPS Growth
- CANF N/A
- NML N/A
- EPS
- CANF N/A
- NML N/A
- Revenue
- CANF $674,000.00
- NML N/A
- Revenue This Year
- CANF $461.72
- NML N/A
- Revenue Next Year
- CANF N/A
- NML N/A
- P/E Ratio
- CANF N/A
- NML N/A
- Revenue Growth
- CANF N/A
- NML N/A
- 52 Week Low
- CANF $1.22
- NML $6.09
- 52 Week High
- CANF $4.69
- NML $7.33
- Technical
- Relative Strength Index (RSI)
- CANF 37.12
- NML 46.19
- Support Level
- CANF $1.22
- NML $7.70
- Resistance Level
- CANF $1.82
- NML $8.42
- Average True Range (ATR)
- CANF 0.13
- NML 0.41
- MACD
- CANF -0.02
- NML -0.02
- Stochastic Oscillator
- CANF 3.13
- NML 58.88
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.